Log in

NASDAQ:EXAS - EXACT Sciences Stock Price, Forecast & News

+3.42 (+3.61 %)
(As of 02/18/2020 01:36 AM ET)
Today's Range
Now: $98.18
50-Day Range
MA: $94.38
52-Week Range
Now: $98.18
Volume1.48 million shs
Average Volume1.63 million shs
Market Capitalization$12.75 billion
P/E RatioN/A
Dividend YieldN/A
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.

Industry, Sector and Symbol

Industry Commercial physical research
Current SymbolNASDAQ:EXAS



Sales & Book Value

Annual Sales$876.29 million
Book Value$5.54 per share


Net Income$-83,990,000.00


Market Cap$12.75 billion
Next Earnings Date5/5/2020 (Estimated)

Receive EXAS News and Ratings via Email

Sign-up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter.

EXACT Sciences (NASDAQ:EXAS) Frequently Asked Questions

What is EXACT Sciences' stock symbol?

EXACT Sciences trades on the NASDAQ under the ticker symbol "EXAS."

How were EXACT Sciences' earnings last quarter?

EXACT Sciences Co. (NASDAQ:EXAS) posted its quarterly earnings results on Tuesday, February, 11th. The medical research company reported $0.54 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.37) by $0.91. The medical research company had revenue of $295.58 million for the quarter, compared to analyst estimates of $294.39 million. EXACT Sciences had a negative return on equity of 28.15% and a negative net margin of 9.59%. View EXACT Sciences' Earnings History.

When is EXACT Sciences' next earnings date?

EXACT Sciences is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for EXACT Sciences.

What guidance has EXACT Sciences issued on next quarter's earnings?

EXACT Sciences updated its FY 2020 After-Hours earnings guidance on Tuesday, February, 11th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.61-1.645 billion, compared to the consensus revenue estimate of $1.59 billion.

What price target have analysts set for EXAS?

16 analysts have issued 1-year price objectives for EXACT Sciences' stock. Their forecasts range from $102.00 to $143.00. On average, they expect EXACT Sciences' stock price to reach $122.93 in the next year. This suggests a possible upside of 25.2% from the stock's current price. View Analyst Price Targets for EXACT Sciences.

What is the consensus analysts' recommendation for EXACT Sciences?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for EXACT Sciences in the last year. There are currently 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for EXACT Sciences.

What are Wall Street analysts saying about EXACT Sciences stock?

Here are some recent quotes from research analysts about EXACT Sciences stock:
  • 1. According to Zacks Investment Research, "Over the past year, Exact Science has been outperforming its industry. The company has demonstrated strength across its entire business, driven by impressive performances with its Cologuard business. It is also progressing well in terms of its three priorities in 2019. We are currently looking forward to Exact Science’s recently-closed merger with advanced molecular diagnostics company Genomic Health. The company exhibited an impressive performance with better-than-expected earnings results in the third quarter of 2019. On the flip side, escalating expenses are putting pressure on operating margin. Sole reliance on Cologuard and competitive headwinds persist as major downsides." (1/21/2020)
  • 2. Canaccord Genuity analysts commented, "We are buyers of EXAS following the unusual 10% weakness in shares today, which we believe were part of the overall selloff today in diagnostics (and software stocks), where much of the alpha in the overall stock market has come from; and what we believe is likely certain funds pressuring EXAS following a cost effectiveness study published last week, but got a lot more attention today on the Street. We believe this is a buy-on- weakness opportunity on shares of EXAS given a handful of deep flaws used in the study." (9/10/2019)

Has EXACT Sciences been receiving favorable news coverage?

Media stories about EXAS stock have trended very negative recently, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. EXACT Sciences earned a daily sentiment score of -3.6 on InfoTrie's scale. They also gave press coverage about the medical research company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for EXACT Sciences.

Are investors shorting EXACT Sciences?

EXACT Sciences saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 15,120,000 shares, an increase of 5.1% from the January 15th total of 14,380,000 shares. Based on an average daily volume of 2,370,000 shares, the short-interest ratio is presently 6.4 days. Approximately 11.8% of the company's shares are short sold. View EXACT Sciences' Current Options Chain.

Who are some of EXACT Sciences' key competitors?

What other stocks do shareholders of EXACT Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other EXACT Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Aduro BioTech (ADRO), salesforce.com (CRM), Paypal (PYPL), AT&T (T), Advanced Micro Devices (AMD) and Square (SQ).

Who are EXACT Sciences' key executives?

EXACT Sciences' management team includes the folowing people:
  • Mr. Kevin T. Conroy, Chairman, Pres & CEO (Age 53)
  • Mr. Jeffrey T. Elliott CFA, Chief Financial Officer (Age 41)
  • Mr. Graham P. Lidgard, Chief Science Officer (Age 70)
  • Mr. D. Scott Coward, Chief Admin. Officer, Sr. VP, Gen. Counsel & Sec. (Age 54)
  • Mr. Mark Stenhouse, Pres of Cologuard (Age 52)

Who are EXACT Sciences' major shareholders?

EXACT Sciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Jennison Associates LLC (4.33%), Artisan Partners Limited Partnership (1.69%), Victory Capital Management Inc. (1.23%), Zevenbergen Capital Investments LLC (1.20%), Victory Capital Management Inc. (1.15%) and Eagle Asset Management Inc. (0.82%). Company insiders that own EXACT Sciences stock include D Scott Coward, G Bradley Cole, Graham Peter Lidgard, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Maneesh Arora, Mark Stenhouse, Michael S Wyzga, Scott C Johnson and Thomas D Carey. View Institutional Ownership Trends for EXACT Sciences.

Which major investors are selling EXACT Sciences stock?

EXAS stock was sold by a variety of institutional investors in the last quarter, including Fred Alger Management LLC, First Trust Advisors LP, Zevenbergen Capital Investments LLC, AJO LP, Dai Ichi Life Insurance Company Ltd, Victory Capital Management Inc., Eagle Asset Management Inc. and Nisa Investment Advisors LLC. Company insiders that have sold EXACT Sciences company stock in the last year include G Bradley Cole, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Mark Stenhouse and Scott C Johnson. View Insider Buying and Selling for EXACT Sciences.

Which major investors are buying EXACT Sciences stock?

EXAS stock was purchased by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Marshall Wace North America L.P., Factory Mutual Insurance Co., D1 Capital Partners L.P., Spyglass Capital Management LLC, Partner Fund Management L.P., Jennison Associates LLC and Eaton Vance Management. View Insider Buying and Selling for EXACT Sciences.

How do I buy shares of EXACT Sciences?

Shares of EXAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is EXACT Sciences' stock price today?

One share of EXAS stock can currently be purchased for approximately $98.18.

How big of a company is EXACT Sciences?

EXACT Sciences has a market capitalization of $12.75 billion and generates $876.29 million in revenue each year. The medical research company earns $-83,990,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis. EXACT Sciences employs 1,977 workers across the globe.View Additional Information About EXACT Sciences.

What is EXACT Sciences' official website?

The official website for EXACT Sciences is http://www.exactsciences.com/.

How can I contact EXACT Sciences?

EXACT Sciences' mailing address is 441 CHARMANY DRIVE, MADISON WI, 53719. The medical research company can be reached via phone at 608-535-8815.

MarketBeat Community Rating for EXACT Sciences (NASDAQ EXAS)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  846 (Vote Outperform)
Underperform Votes:  528 (Vote Underperform)
Total Votes:  1,374
MarketBeat's community ratings are surveys of what our community members think about EXACT Sciences and other stocks. Vote "Outperform" if you believe EXAS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EXAS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/18/2020 by MarketBeat.com Staff

Featured Article: Neutral Rating

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel